China NMPA Product Recall - Tissue-reinforced stapler cartridge

Covidien LLC initiated a voluntary Class I recall in China on January 20, 2012, for specific models of its tissue-reinforced staple cartridges used with anastomosing devices. This action, reported by Covidien Medical Devices Trading (Shanghai) Co., Ltd. and forwarded by the Shanghai Food and Drug Administration, followed reports of 13 serious injuries and 3 deaths globally associated with the Duet TRS product line in thoracic surgery since its 2009 launch. The primary issue involved postoperative chest wall hemorrhage. While animal studies failed to replicate the exact mechanism, Covidien inferred that potentially sharp edges of the device's membrane could scrape against intercostal neurovascular bundles, leading to vascular rupture, especially during lung expansion and contraction. This concern was specifically linked to thoracic applications, with no similar issues reported in abdominal or gynecological surgeries. The National Medical Products Administration (NMPA) document, published February 2, 2012, mandated immediate cessation of sales and a full recall of all affected Duet TRS staple cartridges from the Chinese market. Covidien also collaborated with the US FDA and other global regulators to revise product instructions, prohibiting the device's use in both adult and pediatric patients. This recall highlights a commitment to patient safety following adverse event reports, despite challenges in definitively replicating the cause.